Journal of Clinical Oncology · 2004 · 19 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsTyrosine Kinase InhibitorsEpidermal Growth Factor Receptor InhibitionErlotinib TherapyMedian AgePhase Ii InvestigationPhase Ii ReviewPretreatmentProtein Kinase InhibitorsSmoking History Assessment
7062 Background: The most dramatic benefits seen with epidermal growth factor receptor tyrosine kinase inhibitors in patients with NSCLC occur with BAC. For gefitinib, BAC histology and cigarette smoking history predict sensitivity. We now report pretreatment factors associated with radiographic response after erlotinib (Tarceva) in patients with any BAC features (Ebright MI. Ann Thorac Surg 2002) in tumor specimens. Methods: 127 patients with stage IIIB/IV, inoperable NSCLC underwent central review of biopsies. BAC was found in 65%. To date, 69 have received erlotinib 150mg PO daily. Results: Patients: median age 65 (range 33–85 yrs), 64% women, 26% prior chemotherapy, 91% KPS ≥ 80%, Path: 25%